Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Media 2 Small-Cap Biotechs That Could Reward Patient InvestorsReported by Chris Markoch. Publication Date: 12/12/2025. 
Article Highlights - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Still, if you’re considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and have no commercially available drugs or therapeutics. That means negative earnings (not profitable) and little to no revenue for many of these firms. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. WARNING: Do Not Buy AI Stocks
While NVIDIA wobbles and the Magnificent 7 cool off, there's a backdoor AI play most investors are missing. It's not software. It's not chips. It's the physical infrastructure. The land, buildings, and power that make AI possible. Former Presidential Advisor Brad Thomas says Trump's Executive Orders are about to ignite a boom in this sector. And a small handful of companies are positioned to dominate. He names his top pick - completely free - in this time-sensitive video. Get the name and ticker of his #1 "Mandatory Payout" stock to buy now, FREE Even after a product advances through trials, profitability can be years away. Only when companies reach that milestone do they typically attract the analyst coverage and institutional investment that can materially change their valuations. However, getting in on one of these medical stocks before a breakthrough is like winning the lottery: investors could see 3x, 5x, or even 10x returns. Others may never pan out. That's why many investors who follow penny stocks spread a lump sum across a number of biotech names. If this is a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risk but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny stocks in the sector, Mainz Biomed already has a commercial product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s digital-health pioneers. With more than 60,000 new colorectal cancer cases annually in Germany, the addressable market is sizable. Mainz Biomed is also pursuing a non-invasive blood-based screening test for early pancreatic cancer and reported positive topline results from a feasibility study in October. That program, however, is years away from potential commercialization. Risks are substantial. ColoAlert is not yet available in the United States, and despite early European sales and plans for South American expansion, revenue remains minimal. Reflecting its cash constraints, the company included “going concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering. For now, that appears to be enough to keep the MYNZ share price above $1 and avoid a delisting notice. The company must quickly grow revenue to change its funding picture. If it succeeds, even a small investment could produce a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech with a potentially disruptive approach to antiviral therapy, but it carries the financial risks speculative investors should weigh carefully. The company is developing a novel class of antiviral therapies using its proprietary “nanoviricide” platform. These drug candidates are engineered to mimic human cell surfaces and lure viruses to bind with them, neutralizing the pathogens before they can infect real cells. If validated in human trials, this could represent a fundamentally new method for treating infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. As with many micro-cap biotechs, NanoViricides is pre-revenue and dependent on fresh capital to advance programs. Recent filings indicate limited cash on hand, and investors should expect the possibility of future dilution. Still, if even one candidate advances into clinical development successfully, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
